Abstract library

10 results for "OPS201".
#1801 Peptide Receptor Radionuclide Therapy (PRRT) with a Somatostatin Receptor (SSTR) Antagonist in Patients with SSTR-Positive, Progressive Neuroendocrine Tumours (NETs): A Phase I/II Open-Label Trial to Evaluate the Safety and Preliminary Efficacy of 177Lu-O
Introduction: PRRT with radiolabelled SSTR agonists is highly effective and has become an integral part of NET treatment. Tumour uptake and tumour-to-tissue dose ratios may be higher with radiolabelled SSTR antagonists than agonists. DOTA-JR11 (OPS201) is a very promising next-generation SSTR2-selective antagonist.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Guillaume Nicolas
Keywords: PRRT, 177Lu, OPS201
#2725 Upfront Surgery in Patients with High-Grade GEP NEN and MINEN: A Nordic Multicenter Study of 201 Patients
Introduction: Surgery is the principal treatment for loco-regional gastroenteropancreatic (GEP) neuroendocrine tumors (NET). However, whether surgery is beneficial in high-grade neuroendocrine neoplasms (NEN) and mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN) is not known.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD, PhD Hans-Christian Pommergaard
#54 The clinical challenge of patients with a thoracic or neck neuroendocrine tumor: a retrospective analysis from a single Irish institution
Introduction: Thoracic and neck neuroendocrine tumors (T-N-NETs) represent a rare and intriguing condition and the management of patients with a NET localized at the thorax or neck can be extremely problematic. An expert and multidisciplinary approach is generally required for the optimal management of NET patients. A systematic multidisciplinary approach to NET patients has been recently established at our institution.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Gianluca Tamagno
#1149 Optimal Clinical Effect of Sandostatin LAR Treatment for Gastroenteropancreatic (GEP) Carcinoid
Introduction: The incidence of carcinoid is 2/100 000 with a consistent trend grow due to improved diagnosis of these tumors in recent years. There are two peaks of carcinoid incidence – the first between the 15th and 25th years and the second–between the 65th and 75th years
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: MD Bozhil Robev
Authors: Robev B, Sergieva S, ...
#1712 Epidemiological Factors at Diagnosis in a Large Cohort of Patients with Pancreatic Neuroendocrine Tumours
Introduction: Pancreatic neuroendocrine tumours(pNETs) are among the most frequent NETs with an increasing incidence.However,recent epidemiological data reports are limited.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Apostolos Koffas
#1713 Predictive Factors for Survival in Patients with Pancreatic Neuroendocrine Tumours
Introduction: Pancreatic neuroendocrine tumours(pNETs) comprise a heterogeneous group of neoplasms with rising incidence.However,prognosticators at diagnosis(Dx) are limited.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Apostolos Koffas
#1858 Quality of Life in Patients with Multiple Endocrine Neoplasia Type I (MEN1): Results from the Dutch MEN1 Study Group
Introduction: Multiple Endocrine neoplasia type 1 (MEN1) is a hereditary tumor syndrome, characterized by an increased lifetime risk of benign and malignant endocrine tumors in various organs. Data on quality of life (QoL) in patients with MEN1 are scarce, whereas QoL is considered an important treatment outcome.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: ...none of the above
Presenting Author: MD Rachel van Leeuwaarde
Keywords: MEN1, QoL
#1862 Biphosphonates in Metastatic Bone Disease of Neuroendocrine Neoplasms
Introduction: Metastatic bone disease (mBD) in patients with neuroendocrine neoplasms (NENs) is associated with a more aggressive behaviour
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Others
Presenting Author: MD Krystallenia Alexandraki
Keywords: bone disease
#1880 Dedifferentiation of Metastatic Pancreatic Neuroendocrine Neoplasms
Introduction: Neuroendocrine neoplasms (NENs) exhibit significant differences in growth behavior. Their metastatic disease may dedifferentiate presenting a more aggressive biological behavior
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Krystallenia Alexandraki
#2201 Early Prognostic Factors in Medullary Thyroid Carcinoma
Introduction: Medullary thyroid carcinoma (MTC) prognosis has been related with several variables, being calcitonin doubling time one of the most important prognostic factor. However, it is not evaluable in the early postoperative period.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Endocrine malignancies (MTC, pheochromocytoma) - diagnosis and therapy
Presenting Author: Jose Luis Muñoz de Nova